Jin Kyu Oh
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Jin Kyu Oh has a total of 118 co-authors. Here are the top co-authors by number of shared publications:
Sang Jin Yoon
Department of Urology, Gachon University Gil Medical Center, Incheon, Korea
12 shared publicationsTae Beom Kim
Department of Urology, Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Republic of Korea
11 shared publicationsHan Jung
Department of Urology, Gachon University Gil Medical Center, Incheon, Korea
10 shared publications- Khae Hawn Kim
Department of Urology, Chungnam National University Sejong Hospital, Chungnam National University College of Medicine, Sejong, Korea
9 shared publications - Seung-June Oh
Department of Urology, Seoul National University Hospital, Seoul, Korea
9 shared publications Chang Hee Kim
Department of Urology, Gachon University Gil Medical Center, Gachon University School of Medicine, Incheon, Republic of Korea
7 shared publications
Latest Publications
- Open Access
- 9 September 2023
- Published by Elsevier in Prostate International
- Vol. 11 (4) , 218-221
Artificial intelligence in urologic oncology: the actual clinical practice results of IBM Watson for Oncology in South Korea
- 9 September 2023
- Published by Elsevier in Prostate International
- Vol. 11 (4) , 218-221
Open AccessArtificial intelligence in urologic oncology: the actual clinical practice results of IBM Watson for Oncology in South Korea
- Open Access
- 30 December 2022
- Published by Korean Continence Society in International Neurourology Journal
- Vol. 26 (4) , 268-274
New Trends in Innovative Technologies Applying Artificial Intelligence to Urinary Diseases
Artificial intelligence (AI) is used in various fields of medicine, with applications encompassing all areas of medical services, such as the development of medical robots, the diagnosis and personalized treatment of diseases, and personalized healthcare. Medical AI research and development have been largely focused on diagnosis, prediction, treatment, and management as an auxiliary means of patient care. AI is mainly used in the fields of personal healthcare and diagnostic imaging. In urology, substantial investments are being made in the development of urination monitoring systems in the personal healthcare field and diagnostic solutions for ureteral stricture and urolithiasis in the diagnostic imaging field. This paper describes AI applications for urinary diseases and discusses current trends and future perspectives in AI research.
- 30 December 2022
- Published by Korean Continence Society in International Neurourology Journal
- Vol. 26 (4) , 268-274
Open AccessNew Trends in Innovative Technologies Applying Artificial Intelligence to Urinary Diseases
Artificial intelligence (AI) is used in various fields of medicine, with applications encompassing all areas of medical services, such as the development of medical robots, the diagnosis and personalized treatment of diseases, and personalized healthcare. Medical AI research and development have been largely focused on diagnosis, prediction, treatment, and management as an auxiliary means of patient care. AI is mainly used in the fields of personal healthcare and diagnostic imaging. In urology, substantial investments are being made in the development of urination monitoring systems in the personal healthcare field and diagnostic solutions for ureteral stricture and urolithiasis in the diagnostic imaging field. This paper describes AI applications for urinary diseases and discusses current trends and future perspectives in AI research.
- Open Access
- 30 August 2022
- Published by MDPI AG in Applied Sciences
- Vol. 12 (17) , 8697
Recent Trends in the Diagnostic and Surgical Management of Benign Prostatic Hyperplasia in the U.S. from 2004 to 2017: Annual Changes in the Selection of Treatment Options and Medical Costs
Background: Transurethral resection of the prostate (TURP) is the gold-standard treatment for benign prostatic hyperplasia (BPH). However, laser surgery techniques (e.g., photoselective vaporization of the prostate (PVP), holmium laser, thulium laser enucleation of the prostate (HoLEP or ThuLEP)), and minimally invasive treatment options (e.g., UroLift) are increasingly replacing TURP. This study seeks to report the annual incidence, management trends, and costs of BPH procedures in the U.S. Methods: Data analyses of U.S. health insurance claims from 2004 to 2017, collected from the de-identified Optum Clinformatics Claims Database, were performed to determine the number of BPH patients and the treatment selected. Results: A total of 51,448 patients underwent BPH procedures from 2004 to 2017. There was a significant increase in the annual rate from 770 in 2004 to 6571 in 2017. The mean patient age (±SD) increased from 67.6 years old (±8.4) in 2004 to 73.4 years old (±8.4) in 2017. More than 60% of patients underwent cystourethroscopy and a post-void residual urine check for workup prior to surgical management. TURP was the most-common, and PVP was the second-most-common BPH procedure. Medical and total treatment costs increased, while the detection rate of prostate cancer after BPH surgery gradually decreased from 19.87% in 2004 to 5.78% in 2017. Conclusions: Our study demonstrates a recent trend in BPH management that replaces the traditional TURP technique with alternative methods. Due to rising costs, future studies should assess whether these newer methods are cost effective over the long term.
- 30 August 2022
- Published by MDPI AG in Applied Sciences
- Vol. 12 (17) , 8697
Open AccessRecent Trends in the Diagnostic and Surgical Management of Benign Prostatic Hyperplasia in the U.S. from 2004 to 2017: Annual Changes in the Selection of Treatment Options and Medical Costs
Background: Transurethral resection of the prostate (TURP) is the gold-standard treatment for benign prostatic hyperplasia (BPH). However, laser surgery techniques (e.g., photoselective vaporization of the prostate (PVP), holmium laser, thulium laser enucleation of the prostate (HoLEP or ThuLEP)), and minimally invasive treatment options (e.g., UroLift) are increasingly replacing TURP. This study seeks to report the annual incidence, management trends, and costs of BPH procedures in the U.S. Methods: Data analyses of U.S. health insurance claims from 2004 to 2017, collected from the de-identified Optum Clinformatics Claims Database, were performed to determine the number of BPH patients and the treatment selected. Results: A total of 51,448 patients underwent BPH procedures from 2004 to 2017. There was a significant increase in the annual rate from 770 in 2004 to 6571 in 2017. The mean patient age (±SD) increased from 67.6 years old (±8.4) in 2004 to 73.4 years old (±8.4) in 2017. More than 60% of patients underwent cystourethroscopy and a post-void residual urine check for workup prior to surgical management. TURP was the most-common, and PVP was the second-most-common BPH procedure. Medical and total treatment costs increased, while the detection rate of prostate cancer after BPH surgery gradually decreased from 19.87% in 2004 to 5.78% in 2017. Conclusions: Our study demonstrates a recent trend in BPH management that replaces the traditional TURP technique with alternative methods. Due to rising costs, future studies should assess whether these newer methods are cost effective over the long term.
- Open Access
- 1 November 2018
- Published by Bioscientifica in Endocrine Connections
- Vol. 7 (11) , 1150-1157
Effects of combined growth hormone and testosterone treatments in a rat model of micropenis
Although it is well known that penile growth is dependent on androgens, few clinical studies have reported successful treatment of micropenis with testosterone, likely due to concerns regarding the efficacy and safety of prolonged testosterone use. Thus, we assessed the synergenic effects of growth hormone (GH) treatments with and without testosterone on phallic growth in a rat model of micropenis. Fifty Sprague–Dawley rats were assigned to control (C), microphallus (MP), testosterone, GH (G) and GH plus testosterone (GT) treatment groups, and microphallus was induced by secondary hypogonadism. Pre-pubertal treatments with testosterone, GH or the combination were initiated from 7 days after birth and were maintained until 12 weeks of age. To assess the efficacy of treatments, phallic dimensions were determined and histological markers of cavernosal integrity were evaluated. Skeletal and gonadal safety profiles of the treatments were then assessed according to right tibial lengths and testicular weights, respectively. No monotreatments normalised penile dimensions, whereas combination treatments led to complete restoration. The combination treatment also prevented decreases in histological indicators of cavernosal integrity, including smooth muscle actin and collagen III expression levels and fat globule accumulation and sinusoidal density. These synergenic effects of GH treatments on penile growth may follow changes in androgen receptor expression levels and were accompanied by decreased testicular volume losses. Although the physiological conditions of phallic growth differ between humans and rats, this proof-of-concept study provides a strategy for circumventing the problems of testosterone monotherapy for human micropenis.
- 1 November 2018
- Published by Bioscientifica in Endocrine Connections
- Vol. 7 (11) , 1150-1157
Open AccessEffects of combined growth hormone and testosterone treatments in a rat model of micropenis
Although it is well known that penile growth is dependent on androgens, few clinical studies have reported successful treatment of micropenis with testosterone, likely due to concerns regarding the efficacy and safety of prolonged testosterone use. Thus, we assessed the synergenic effects of growth hormone (GH) treatments with and without testosterone on phallic growth in a rat model of micropenis. Fifty Sprague–Dawley rats were assigned to control (C), microphallus (MP), testosterone, GH (G) and GH plus testosterone (GT) treatment groups, and microphallus was induced by secondary hypogonadism. Pre-pubertal treatments with testosterone, GH or the combination were initiated from 7 days after birth and were maintained until 12 weeks of age. To assess the efficacy of treatments, phallic dimensions were determined and histological markers of cavernosal integrity were evaluated. Skeletal and gonadal safety profiles of the treatments were then assessed according to right tibial lengths and testicular weights, respectively. No monotreatments normalised penile dimensions, whereas combination treatments led to complete restoration. The combination treatment also prevented decreases in histological indicators of cavernosal integrity, including smooth muscle actin and collagen III expression levels and fat globule accumulation and sinusoidal density. These synergenic effects of GH treatments on penile growth may follow changes in androgen receptor expression levels and were accompanied by decreased testicular volume losses. Although the physiological conditions of phallic growth differ between humans and rats, this proof-of-concept study provides a strategy for circumventing the problems of testosterone monotherapy for human micropenis.
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (4S)
PD64-10 LONG-TERM OUTCOMES OF LASER PROSTATECTOMY FOR STORAGE SYMPTOMS: COMPARISON OF SERIAL 5-YEAR FOLLOW-UP DATA BETWEEN 120W HPS PHOTO-SELECTIVE VAPORIZATION OF THE PROSTATE AND HOLMIUM LASER ENUCLEATION OF THE PROSTATE
- 1 April 2018
- Published by Wolters Kluwer Health in Journal of Urology
- Vol. 199 (4S)
PD64-10 LONG-TERM OUTCOMES OF LASER PROSTATECTOMY FOR STORAGE SYMPTOMS: COMPARISON OF SERIAL 5-YEAR FOLLOW-UP DATA BETWEEN 120W HPS PHOTO-SELECTIVE VAPORIZATION OF THE PROSTATE AND HOLMIUM LASER ENUCLEATION OF THE PROSTATE
- Open Access
- 1 January 2018
- Published by XMLink in The World Journal of Men's Health
- Vol. 36 (1) , 79-86
Enucleated Weight/Enucleation Time, Is It Appropriate for Estimating Enucleation Skills for Holmium Laser Enucleation of the Prostate? A Consideration of Energy Consumption
Kim KH, et al. World J Mens Health. 2017 Sep;35:e22. https://doi.org/10.5534/wjmh.17039
- 1 January 2018
- Published by XMLink in The World Journal of Men's Health
- Vol. 36 (1) , 79-86
Open AccessEnucleated Weight/Enucleation Time, Is It Appropriate for Estimating Enucleation Skills for Holmium Laser Enucleation of the Prostate? A Consideration of Energy Consumption
Kim KH, et al. World J Mens Health. 2017 Sep;35:e22. https://doi.org/10.5534/wjmh.17039
- Open Access
- 1 September 2017
- Published by Elsevier in Prostate International
- Vol. 5 (3) , 113-118
Efficacy and safety of silodosin in the treatment of lower urinary tract symptoms in elderly men taking antihypertensive medications
- 1 September 2017
- Published by Elsevier in Prostate International
- Vol. 5 (3) , 113-118
Open AccessEfficacy and safety of silodosin in the treatment of lower urinary tract symptoms in elderly men taking antihypertensive medications
- Open Access
- 1 January 2017
- Published by The Korean Urological Association in Investigative and Clinical Urology
- Vol. 58 (3) , 200-204
Measuring change in prostate size after holmium laser enucleation: A prospective study
Oh JK, et al. Investig Clin Urol. 2017 May;58(3):200-204. https://doi.org/10.4111/icu.2017.58.3.200
- 1 January 2017
- Published by The Korean Urological Association in Investigative and Clinical Urology
- Vol. 58 (3) , 200-204
Open AccessMeasuring change in prostate size after holmium laser enucleation: A prospective study
Oh JK, et al. Investig Clin Urol. 2017 May;58(3):200-204. https://doi.org/10.4111/icu.2017.58.3.200